Extensive Stage Small Cell Lung Cancer Study

The purpose of this study is to learn more about how an investigational drug (tarlatamab) works in people with extensive-stage small cell lung cancer. In this study, we want to learn more about its safety and tolerability (effects good or bad) when used in combination with one of two other drugs (atezolizumab or durvalumab). We also want to learn more about the combination of the study drug with either atezolizumab or durvalumab and carboplatin and etopopside.